

DAFTAR PUSTAKA

- Amary, F., Berisha, F., Ye, H., Gupta, M., Gutteridge, A., Baumhoer, D., Gibbons, R., Tirabosco, R., O'Donnell, P., & Flanagan, A. M. (2017). H3F3A (Histone 3.3) G34W Immunohistochemistry. *American Journal of Surgical Pathology*, 41(8), 1059–1068. <https://doi.org/10.1097/PAS.0000000000000859>
- Amri, R., Charfi, S., Jemaà, M., Miled, N., Slimi, F., Rebai, M. A., Abdelwahed, M., Keskes, H., & Aifa, S. (2020). Significance of EGFR/HER2 Expression and PIK3CA Mutations in Giant Cell Tumour of Bone Development. *BioMed Research International*, 2020. <https://doi.org/10.1155/2020/2931784>
- Anatomy & Physiology. (2017). In *Anatomy & Physiology*. <https://doi.org/10.5399/osu/1116>
- Authors, S. C., Of, N., & At, A. (1934). II. Anatomy and physiology. In *Acta Oto-Laryngologica* (Vol. 19, Issue S20). <https://doi.org/10.3109/00016483409122096>
- Behjati, S., Tarpey, P. S., Presneau, N., Scheipl, S., Pillay, N., Van Loo, P., Wedge, D. C., Cooke, S. L., Gudem, G., Davies, H., Nik-Zainal, S., Martin, S., McLaren, S., Goodie, V., Robinson, B., Butler, A., Teague, J. W., Halai, D., Khatri, B., ... Flanagan, A. M. (2013). Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. *Nature Genetics*, 45(12), 1479–1482. <https://doi.org/10.1038/ng.2814>
- Cao, H., Lin, F., Hu, Y., Zhao, L., Yu, X., Wang, Z., Ye, Z., Wu, S., Guo, S., Zhang, G., & Wang, J. (2017). Epidemiological and Clinical Features of Primary Giant Cell Tumors of the Distal Radius: A Multicenter Retrospective Study in China. *Scientific Reports*, 7(1), 1–6. <https://doi.org/10.1038/s41598-017-09486-6>
- Chen, S., Li, C., Wu, B., Zhang, C., Liu, C., Lin, X., Wu, X., Sun, L., Liu, C., Chen, B. O., Zhong, Z., Xu, L., & Li, E. (2014). Identification of differentially expressed genes and their subpathways in recurrent versus primary bone giant cell tumors. *International Journal of Oncology*, 45(3), 1133–1142. <https://doi.org/10.3892/ijo.2014.2501>
- Cheng, D. D., Hu, T., Zhang, H. Z., Huang, J., & Yang, Q. C. (2015). Factors Affecting the Recurrence of Giant Cell Tumor of Bone after Surgery: A Clinicopathological Study of 80 Cases from a Single Center. *Cellular Physiology and Biochemistry*, 36(5), 1961–1970. <https://doi.org/10.1159/000430164>

- Cleven, A. H. G., Höcker, S., Briaire-De Bruijn, I., Szuhai, K., Cleton-Jansen, A. M., & Bovée, J. V. M. G. (2015). Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. *American Journal of Surgical Pathology*, 39(11), 1576–1583. <https://doi.org/10.1097/PAS.0000000000000512>
- Conti, A., Rodriguez, G. C., Chiechi, A., Blazquez, R. M. D., Barbado, V., Krènacs, T., Novello, C., Pazzaglia, L., Quattrini, I., Zanella, L., Picci, P., De Alava, E., & Benassi, M. S. (2011). Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis. *American Journal of Pathology*, 178(1), 88–97. <https://doi.org/10.1016/j.ajpath.2010.11.035>
- David, & Fajar, A. (2006). Pengobatan mutakhir giant cell tumor tulang (osteoklastoma). *Universa Medicina*, 25(2).
- Flanagan, A. M., Tirabosco, R., Gikas, P. D., & Bone, O. N. O. F. (2015). and Molecular Overview. In *Bone Cancer* (Second Edi). Elsevier Inc. <https://doi.org/10.1016/B978-0-12-416721-6/00023-6>
- Georgiev, G. P., Slavchev, S., Dimitrova, I., & Landzhov, B. (2015). Giant cell tumor of bone: current review of morphological, clinical, radiological, and therapeutic characteristics. *Journal of Clinical and Experimental Investigations*, 5(3), 475–485. <https://doi.org/10.5799/ahinjs.01.2014.03.0445>
- He, Y., Zhang, J., & Ding, X. (2017). Prognosis of local recurrence in giant cell tumour of bone: what can we do? *Radiologia Medica*, 122(7), 505–519. <https://doi.org/10.1007/s11547-017-0746-6>
- Heijden, L. Van Der, Dijkstra, S., & Gelderblom, H. (2020). *Current concepts in the treatment of giant cell tumour of bone*. May. <https://doi.org/10.1097/CCO.0000000000000645>
- Julian Lüke, Alexandra von Baer, Schreiber, J., & Lübbehüsen, C. (2017). *H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant*. pmid: 28211081 DOI: 10.1111/his.13190%0A
- Kim, Y., Nizami, S., Goto, H., & Lee, F. Y. (2012). Modern interpretation of giant cell tumor of bone: Predominantly osteoclastogenic stromal tumor. *Clinics in Orthopedic Surgery*, 4(2), 107–116. <https://doi.org/10.4055/cios.2012.4.2.107>
- Liede, A., Hernandez, R. K., Tang, E. T., Li, C., Bennett, B., Wong, S. S., & Jandial, D. (2018). Epidemiology of benign giant cell tumor of bone in the Chinese population. *Journal of Bone Oncology*, 12, 96–100. <https://doi.org/10.1016/j.jbo.2018.07.003>

- Lim, J., Park, J. H., Baude, A., Yoo, Y., Lee, Y. K., Schmidt, C. R., Park, J. B., Fellenberg, J., Zustin, J., Haller, F., Krücken, I., Kang, H. G., Park, Y. J., Plass, C., & Lindroth, A. M. (2017). The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing. *Scientific Reports*, 7(1), 1–14. <https://doi.org/10.1038/s41598-017-13887-y>
- Lokuhetty D,A. White V, A. C. I. (Ed.). (2020). *WHO Classification of Tumours Soft tissue and bone tumours* (5th ed.). International Agency for Research on Cancer (IARC) 150 Cours Albert Thomas 69372 Lyon Cedex 08, France. <https://doi.org/10.1017/CBO9780511545375.031>
- Lübbehüsen, C., Lüke, J., Seeling, C., Mellert, K., Marienfeld, R., von Baer, A., Schultheiss, M., Möller, P., & Barth, T. F. E. (2019). Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway. *Scientific Reports*, 9(1), 1–10. <https://doi.org/10.1038/s41598-019-42611-1>
- Lujic, N., Sopta, J., Kovacevic, R., Stevanovic, V., & Davidovic, R. (2016). Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β -catenin and Ki67. *International Orthopaedics*, 40(11), 2393–2399. <https://doi.org/10.1007/s00264-016-3292-2>
- Noh, B. J., & Park, Y. K. (2018). Giant cell tumor of bone: updated molecular pathogenesis and tumor biology. *Human Pathology*, 81, 1–8. <https://doi.org/10.1016/j.humpath.2018.06.017>
- Rosenberg, N. and. (2019). Diagnostic pathology Bone (secod edition). In *Journal of Chemical Information and Modeling* (Vol. 53, Issue 9).
- Salsabila, J. (2020). *Prevalensi dan Karakteristik Klinis Giant Cell Tumor of Bone di RSUP Dr. Mohammad Hoesin Palembang Periode 2 Januari 2015-31 Desember 2019*.
- Scotto, F., Whyte, M. P., & Gianfrancesco, F. (2020). The two faces of giant cell tumor of bone. *Cancer Letters*, 489(May), 1–8. <https://doi.org/10.1016/j.canlet.2020.05.031>
- Siddiqui, M. A., Seng, C., & Tan, M. H. (2014). Risk factors for recurrence of giant cell tumours of bone. *Journal of Orthopaedic Surgery*, 22(1), 108–110. <https://doi.org/10.1177/230949901402200127>
- Sobti, A., Agrawal, P., Agarwala, S., & Agarwal, M. (2016). Giant cell tumor of bone - An overview. *Archives of Bone and Joint Surgery*, 4(1), 2–9. <https://doi.org/10.22038/abjs.2016.4701>
- Thompson, W. R., Rubin, C. T., & Rubin, J. (2012). Mechanical regulation of signaling pathways in bone. *Gene*, 503(2), 179–193.

<https://doi.org/10.1016/j.gene.2012.04.076>

- Trovato, M., Patil, V., Gehre, M., & Noh, K. M. (2020). *Histone Variant H3.3 Mutations in Defining the Chromatin Function in Mammals*.
- Unni, KK, & Inwards, CY (2010). *Dahlin's Bone Tumors*. Lippincott Williams & Wilkins
- Yamamoto, H., Ishihara, S., Toda, Y., & Oda, Y. (2020). Histone H3.3 mutation in giant cell tumor of bone: an update in pathology. *Medical Molecular Morphology*, 53(1). <https://doi.org/10.1007/s00795-019-00238-1>
- Yoshida, K. ichi, Nakano, Y., Honda-Kitahara, M., Wakai, S., Motoi, T., Ogura, K., Sano, N., Shibata, T., Okuma, T., Iwata, S., Kawai, A., Ichimura, K., & Yoshida, A. (2019). Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone. *Modern Pathology*, 32(12), 1751–1761. <https://doi.org/10.1038/s41379-019-0318-5>
- Zheng, M. H., Robbins, P., Xu, J., Huang, L., Wood, D. J., & Papadimitriou, J. M. (2001). The histogenesis of giant cell tumour of bone: A model of interaction between neoplastic cells and osteoclasts. *Histology and Histopathology*, 16(1), 297–307. <https://doi.org/10.14670/HH-16.297>

Lampiran 1

LAMPIRAN
DATA SAMPEL

NO	UMUR (Th)	UMUR	JENIS KELAMIN	INTENSITAS	PERSENTASE LUAS AREA	PERSENTASE	SCORE	EKSPRESI SKOR	LOKASI	TULANG PANJANG/ NON-TULANG PANJANG	KLASIFIKASI GCTB	STATUS GCTB/ NON-GCTB
1	46	3	1	3	90	3	270	2	2	1	1	1
2	35	2	2	3	80	3	240	2	8	2	2	1
3	36	2	1	1	60	3	60	2	2	1	1	1
4	57	3	1	2	50	3	100	2	2	1	4	1
5	26	2	1	2	40	2	80	2	2	1	1	1
6	23	2	2	0	0	0	0	1	8	2	5	2
7	41	3	1	3	70	3	210	2	8	2	1	1
8	40	2	1	0	0	0	0	1	8	2	5	2
9	53	3	2	3	70	3	210	2	2	1	1	1
10	44	3	1	3	80	3	240	2	5	1	2	1
11	52	3	1	2	70	3	140	2	6	1	1	1
12	20	2	2	0	0	0	0	1	8	2	5	2
13	27	2	2	0	0	0	0	1	8	2	5	2
14	21	2	1	0	0	0	0	1	4	1	5	2
15	54	3	2	0	0	0	0	1	8	2	5	2
16	53	3	1	3	60	3	180	2	6	1	1	1
17	21	2	1	3	90	3	270	2	5	1	3	1
18	40	2	2	2	40	2	80	2	2	1	2	1
19	25	2	1	2	70	3	140	2	5	1	1	1
20	48	3	1	0	0	0	0	1	1	1	1	1
21	42	3	2	0	0	0	0	1	8	2	5	2

22	37	2	1	3	90	3	270	2	6	1	1	1
23	32	2	1	3	70	3	210	2	1	1	2	1
24	24	2	1	3	80	3	240	2	5	1	1	1
25	25	2	1	2	60	3	120	2	2	1	3	1
26	37	2	2	1	50	3	50	2	6	1	3	1
27	28	2	2	0	0	0	0	1	8	2	2	1
28	24	2	2	2	60	3	120	2	5	1	3	1
29	48	3	2	1	70	3	70	2	8	2	3	1
30	29	2	1	0	0	0	0	1	8	2	5	2
31	25	2	2	3	90	3	270	2	6	1	1	1
32	38	2	2	2	60	3	120	2	8	2	3	1
33	48	3	2	2	70	3	140	1	3	1	1	1
34	52	3	2	0	0	0	0	1	1	1	3	1
35	44	3	2	3	80	3	240	2	5	1	1	1
36	33	2	2	3	70	3	210	2	2	1	1	1
37	51	3	1	0	0	0	0	1	8	2	3	1
38	70	3	2	0	0	0	0	1	8	2	5	2
39	44	3	1	3	70	3	210	2	2	1	1	1
40	30	2	2	3	80	3	240	2	2	1	1	1
41	40	2	1	2	60	3	120	2	2	1	1	1
42	35	2	2	1	8	1	8	1	8	2	1	1
43	41	3	1	0	0	0	0	1	1	1	1	1
44	19	1	1	1	7	1	7	1	2	1	1	1
45	45	3	2	0	0	0	0	1	4	1	4	1
46	39	2	2	0	0	0	0	1	8	2	5	2
47	17	1	1	3	60	3	180	2	8	2	1	1
48	40	2	2	0	0	0	0	1	6	1	4	1
49	24	2	1	3	90	3	270	2	2	1	1	1
50	14	1	2	0	0	0	0	1	6	1	5	2

51	45	3	2	3	80	3	240	2	5	1	1	1
52	24	2	1	3	90	3	270	2	2	1	1	1
53	21	2	1	0	0	0	0	1	5	1	1	1
54	20	2	1	0	0	0	0	1	6	1	5	2
55	34	2	1	3	90	3	270	2	5	1	1	1
56	40	2	2	0	0	0	0	1	8	2	5	2
57	15	1	1	3	90	3	270	2	8	2	1	1
58	41	3	1	3	70	3	210	2	7	1	1	1
59	16	1	1	0	0	0	0	1	8	2	5	2
60	45	3	1	3	80	3	240	2	5	1	1	1
61	18	1	1	0	0	0	0	1	7	1	5	2
62	17	1	1	0	0	0	0	1	8	2	5	2
63	61	3	2	3	70	3	210	2	8	2	1	1
64	34	2	1	2	40	2	80	2	6	1	1	1
65	37	2	2	3	70	3	210	2	2	1	1	1

66	20	2	2	3	80	3	240	2	1	1	1	1
67	27	2	2	0	0	0	0	1	4	1	3	1
68	43	3	1	3	90	3	270	2	3	1	1	1
69	16	1	2	0	0	0	0	1	5	1	5	2
70	51	3	1	3	70	3	210	2	2	1	1	1
71	62	3	1	0	0	0	0	1	5	1	1	1

UMUR	JENIS KELAMIN	INTENSITAS	EKSPRESI	LOKASI	JENIS TULANG	KLASIFIKASI GCTB	STATUS
1= <20TH	LAKI = 1	0= Tidak terwarnai	1= NEGATIF (<=3%)	1= PROXIMAL HUMERUS	1= TULANG PANJANG	1=PRIMER	1= GCTB
2= 20-40TH	WANITA = 2	1= Positif Lemah	2= POSITIF (>3%)	2= DISTAL RADIUS	2= NON TULANG PANJANG	2=REKURREN	2= NON GCTB
3= >40TH		2= Positif Sedang		3= DISTAL ULNA		3=METASTASIS	
		3= Positif Kuat		4= PROXIMAL FEMUR		4=MALIGNANT	
				5= DISTAL FEMUR		5= LESI GIANT CELL NON-GCTB	
				6= PROXIMAL TIBIA			
				7= DISTAL TIBIA			
				8= LOKASI LAIN			

KET: KUNING (NON GCTB)

Lampiran 2



REKOMENDASI PERSETUJUAN ETIK

Nomor : 585/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 10 September 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21080529	No Sponsor	Protokol
Peneliti Utama	dr. Futriani	Sponsor	
Judul Peneliti	EKSPRESI HISTON H3.3 (G34W) PADA GIANT CELL TUMOR OF BONE		
No Versi Protokol	1	Tanggal Versi	30 Agustus 2021
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan